Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. S&P 500 (SPY)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 54.07B | 45.81B | 44.35B | 37.42B | 26.62B | Gross Profit |
| 43.87B | 37.77B | 31.96B | 24.98B | 21.32B | EBIT |
| 10.00B | 8.19B | 3.76B | 1.06B | 5.16B | EBITDA |
| 17.12B | 13.91B | 9.09B | 5.11B | 8.08B | Net Income Common Stockholders |
| 7.04B | 5.96B | 3.29B | 112.00M | 3.20B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 5.65B | 5.86B | 6.41B | 6.40B | 7.99B | Total Assets |
| 104.03B | 101.12B | 96.48B | 105.36B | 66.73B | Total Debt |
| 30.11B | 28.62B | 29.23B | 30.78B | 20.38B | Net Debt |
| 24.63B | 22.78B | 23.07B | 24.45B | 12.55B | Total Liabilities |
| 63.16B | 61.95B | 59.42B | 66.08B | 51.09B | Stockholders Equity |
| 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
| Cash Flow | Free Cash Flow | |||
| 7.28B | 6.57B | 7.24B | 3.76B | 2.19B | Operating Cash Flow |
| 11.86B | 10.35B | 9.81B | 5.96B | 4.80B | Investing Cash Flow |
| -7.98B | -4.06B | -2.96B | -11.06B | -285.00M | Financing Cash Flow |
| -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | £3.98B | 14.13 | 15.79% | 3.45% | 5.83% | 83.35% | |
75 Outperform | £155.93B | 28.31 | 17.43% | 2.44% | 14.82% | 14.98% | |
70 Outperform | £54.07B | 21.08 | 19.06% | 4.58% | 3.46% | -48.06% | |
54 Neutral | £912.72M | ― | ― | 5.76% | -729.39% | ||
48 Neutral | $6.27B | 1.17 | -48.19% | 2.68% | 17.28% | 1.24% |
AstraZeneca Earnings Call Summary
AstraZeneca Corporate Events
AstraZeneca’s Imfinzi, in combination with chemotherapy, has been approved by the European Union for treating resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This approval is based on the AEGEAN Phase III trial, which demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval marks a significant step in improving outcomes for NSCLC patients in Europe, offering a new immunotherapy-based regimen that extends the time patients live without cancer recurrence. This development underscores AstraZeneca’s commitment to transforming care in early-stage lung cancer, where there is significant potential for cure.
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved by the European Union as the first HER2-directed therapy for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer following endocrine therapy. This approval, based on the DESTINY-Breast06 Phase III trial results, positions Enhertu as a superior alternative to chemotherapy, offering a median progression-free survival of over a year. The approval expands the eligible patient population and marks a significant advancement in breast cancer treatment, potentially impacting AstraZeneca’s market positioning and providing new treatment options for patients.
AstraZeneca PLC has announced its issued share capital with voting rights as of March 31, 2025, totaling 1,550,623,487 ordinary shares. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
AstraZeneca’s Calquence, in combination with bendamustine and rituximab, has been recommended for approval by the CHMP in the EU for first-line treatment of mantle cell lymphoma (MCL), marking it as the first BTK inhibitor for this indication. The recommendation is based on the ECHO Phase III trial results, which showed a significant improvement in progression-free survival, potentially transforming the standard of care for MCL patients in Europe.
AstraZeneca’s Imfinzi has been approved by the FDA as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) in the US, following the successful NIAGARA Phase III trial. This approval marks a significant advancement in treatment, offering a new standard of care by reducing the risk of disease recurrence and death, and is expected to transform clinical approaches to MIBC, providing new hope for patients and stakeholders.
AstraZeneca has announced a $2.5 billion investment to establish a new global strategic R&D center in Beijing, marking its second in China and sixth worldwide. This initiative, in partnership with the Beijing Municipal Government, includes collaborations with biotech firms Harbour BioMed, Syneron Bio, and BioKangtai, and aims to advance life sciences in China. The investment will enhance AstraZeneca’s early-stage research and clinical development capabilities, supported by a state-of-the-art AI and data science laboratory. Additionally, AstraZeneca is forming a joint venture with BioKangtai to develop vaccines, marking its first vaccine manufacturing facility in China. This strategic move is expected to grow AstraZeneca’s Beijing workforce to 1,700 employees and strengthen its position in the global biopharmaceutical industry.
AstraZeneca announced that its investigational drug eneboparatide met the primary endpoint in the Phase III CALYPSO trial, showing significant efficacy in normalizing serum calcium levels in adults with chronic hypoparathyroidism at 24 weeks. This result highlights eneboparatide’s potential as a new treatment option for this rare endocrine disorder, which affects over 200,000 people in the US and EU. The trial will continue to 52 weeks to further assess the drug’s risk-benefit profile, with full data expected to be shared with global health authorities and presented at medical meetings.
AstraZeneca’s Imfinzi has been approved by the European Union as the first immunotherapy for limited-stage small cell lung cancer (LS-SCLC), following the successful ADRIATIC Phase III trial. This approval marks a significant advancement in treatment options, as Imfinzi demonstrated a 27% reduction in the risk of death compared to placebo, offering a new benchmark for LS-SCLC care and potentially transforming outcomes for patients in Europe.
AstraZeneca has announced its acquisition of EsoBiotec, a biotechnology company specializing in in vivo cell therapies, for up to $1 billion. This acquisition includes EsoBiotec’s ENaBL platform, which could revolutionize cell therapy by allowing treatments to be delivered in minutes rather than weeks, potentially transforming the patient experience and expanding access to these therapies. The move is expected to enhance AstraZeneca’s cell therapy capabilities and accelerate its ambition to harness the full potential of cell therapies, marking a significant step forward in its oncology and immune-mediated disease treatment strategies.
The Capital Group Companies, Inc., a U.S.-based investment management firm, has increased its voting rights in AstraZeneca PLC to 5.000629% as of March 10, 2025. This acquisition of voting rights highlights the firm’s strategic interest in AstraZeneca, potentially impacting the company’s shareholder dynamics and signaling confidence in AstraZeneca’s market positioning.
AstraZeneca PLC announced that on March 4, 2025, its CEO Pascal Soriot and CFO Aradhana Sarin received awards of ordinary shares under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). These awards are part of the company’s incentive plans, with shares under the AZDBP representing deferred portions of annual bonuses and subject to a three-year holding period. The AZPSP awards are contingent on performance measures over three years, with a subsequent two-year holding period, reflecting AstraZeneca’s focus on aligning executive compensation with long-term performance goals.
AstraZeneca PLC announced that as of 28 February 2025, its issued share capital with voting rights consists of 1,550,607,175 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
AstraZeneca’s Imfinzi, in combination with chemotherapy, has been recommended for approval by the CHMP in the EU for treating adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This recommendation is based on the AEGEAN Phase III trial results, which demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval could significantly enhance AstraZeneca’s position in the oncology market, providing a new treatment option for patients with early-stage lung cancer, addressing a high unmet medical need.
AstraZeneca, in collaboration with Daiichi Sankyo, announced that their drug Enhertu has been recommended for approval in the EU for treating patients with HER2-low or HER2-ultralow metastatic breast cancer, based on the DESTINY-Breast06 Phase III trial results. This recommendation by the Committee for Medicinal Products for Human Use (CHMP) marks a significant advancement in breast cancer treatment, offering a new HER2-directed therapy option for patients who have progressed on endocrine therapy, potentially improving outcomes and shifting current treatment paradigms.
AstraZeneca announced positive interim results from the SERENA-6 Phase III trial, where its drug camizestrant, combined with CDK4/6 inhibitors, showed significant improvement in progression-free survival for patients with HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. This marks the first time a next-generation oral SERD has demonstrated such benefits in the first-line setting, potentially shifting clinical practice and offering a new standard-of-care for these patients. The trial’s design, using ctDNA to guide treatment switches, highlights a novel approach in managing endocrine resistance, with implications for future breast cancer therapies.
AstraZeneca announced the filing of its 2024 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing stakeholders access to its complete audited financial statements. This filing underscores AstraZeneca’s transparency and commitment to compliance, which can enhance trust among investors and affirm its strong position in the biopharmaceutical industry.
The Capital Group Companies, Inc., a major investment management company based in Los Angeles, has acquired a significant stake in AstraZeneca PLC, crossing a 5% threshold of voting rights on January 29, 2025. This acquisition highlights Capital Group’s strategic interest in AstraZeneca’s operations, potentially influencing the company’s future governance and strategic decisions.
AstraZeneca PLC has published its Annual Report and Form 20-F Information for 2024, which is available on the company’s website and will soon be accessible via the National Storage Mechanism. The report includes key regulated information such as principal risks, directors’ responsibilities, and related party transactions. The company’s Annual General Meeting is scheduled for April 11, 2025. This announcement highlights AstraZeneca’s commitment to transparency and regulatory compliance, potentially influencing its stakeholders and market positioning.
AstraZeneca announced proposed board changes with Karen Knudsen, a recognized cancer scientist, being nominated as a Non-Executive Director at the upcoming AGM in April 2025. Knudsen, known for her work in oncology and healthcare innovation, is set to join the Science and Sustainability Committees. Concurrently, Deborah DiSanzo and Andreas Rummelt will retire from the board. These changes reflect AstraZeneca’s strategic focus on enhancing its expertise in science and sustainability, potentially influencing its industry positioning and operations.
AstraZeneca reported a robust financial performance for the year 2024, with Total Revenue increasing by 21% and Core EPS growing by 19%. The growth was primarily driven by strong sales across its key therapeutic areas, including a 24% rise in oncology. The company also achieved milestones in drug approvals in various regions and announced plans to increase dividends and capital expenditure in 2025. Furthermore, AstraZeneca is facing a legal issue in China regarding unpaid importation taxes, which it is cooperating with authorities to resolve.
AstraZeneca PLC announced that as of 31 January 2025, its issued share capital with voting rights comprises 1,550,581,134 ordinary shares. This figure is crucial for shareholders to determine their notification requirements under the UK’s Financial Conduct Authority’s Disclosure and Transparency Rules, indicating transparency in the company’s voting rights structure and facilitating shareholder engagement.
AstraZeneca’s Imfinzi has been recommended for approval in the European Union as the first immunotherapy for limited-stage small cell lung cancer (LS-SCLC) based on the ADRIATIC Phase III trial, which demonstrated a significant survival benefit. This recommendation is expected to enhance AstraZeneca’s position in the oncology market by providing a new treatment option for LS-SCLC patients, potentially improving survival rates and offering a practice-changing therapy in Europe.
AstraZeneca and Daiichi Sankyo’s Enhertu has received FDA approval in the US for treating patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after disease progression on endocrine therapies. This approval, based on the DESTINY-Breast06 Phase III trial results, marks a significant advancement by allowing a new treatment option that offers a median progression-free survival of over a year, positioning Enhertu as a potential new standard of care and broadening the patient population eligible for HER2-directed therapies.
AstraZeneca, in collaboration with Daiichi Sankyo, has received its first US approval for Datroway (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate, for treating previously treated metastatic HR-positive, HER2-negative breast cancer. The approval, based on the TROPION-Breast01 Phase III trial results, marks a significant milestone in offering a new treatment option, reducing disease progression or death risk by 37% compared to chemotherapy, thereby advancing AstraZeneca’s goal to provide innovative cancer therapies.
AstraZeneca announced the US FDA approval of Calquence in combination with bendamustine and rituximab for previously untreated mantle cell lymphoma (MCL) patients, marking the first BTK inhibitor approved for first-line MCL treatment. This approval, based on ECHO Phase III trial results, enhances AstraZeneca’s position in oncology by offering a new treatment option for a rare and aggressive cancer, thus potentially transforming MCL patient care and reinforcing Calquence as a key therapy in blood cancers.